NCT00336765View on ClinicalTrials.gov

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

August 31, 2010

Study Completion Date

September 30, 2010

Conditions
Cancer
Interventions
DRUG

XL647

Tablets supplied in 50-mg strength administered orally daily

Trial Locations (2)

55905

Mayo Clinic, Rochester

94305

Stanford University Medical Center, Stanford

All Listed Sponsors
lead

Kadmon Corporation, LLC

INDUSTRY

NCT00336765 - Study of XL647 Administered Orally Daily to Patients With Solid Tumors | Biotech Hunter | Biotech Hunter